ARNI Versus Perindopril for Remodeling in HFrEF. A Cohort Study

ARNI Versus Perindopril for Remodeling in HFrEF. A Cohort Study

Introduction: Ventricular remodeling is a mal-adaptive process. Both angiotensin-converting enzyme inhibitors and sacubitril/valsartan have been shown to reverse remodeling in mostly uncontrolled observational studies. There is a lack of head-to-head studies. Methods: This cohort study compares the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular pharmacology and therapeutics 2023-01, Vol.28, p.10742484231195019-10742484231195019
Hauptverfasser: Bin Atan, Noor Muhammad Azlan Shah, Bin Hadi, Mohd Firdaus, Teoh, Victoria Wen Yeng, Danaee, Mahmoud, Loch, Alexander
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction: Ventricular remodeling is a mal-adaptive process. Both angiotensin-converting enzyme inhibitors and sacubitril/valsartan have been shown to reverse remodeling in mostly uncontrolled observational studies. There is a lack of head-to-head studies. Methods: This cohort study compares the remodeling effects of angiotensin receptor blockers combined with a neprilysin inhibitor (ARNI) and perindopril in heart failure with reduced ejection fraction (HFrEF) patients between January 2017 and December 2020. Inclusion criteria: (i) age > 18 years, (ii) recent diagnosis of de-novo HFrEF (EF 
ISSN:1074-2484
1940-4034
DOI:10.1177/10742484231195019